Rani Therapeutics Holdings Inc (RANI)

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company listed on NASDAQ under the ticker RANI. The company is focused on developing oral delivery technology for biologic drugs and other therapies, with the goal of providing an alternative to injectable administration for patients, physicians, and healthcare systems in the United States. Its main platform, the RaniPill capsule, is designed as a drug-agnostic oral delivery system for substances such as oligonucleotides, peptides, proteins, and antibodies.

The company’s pipeline includes RT-102, a parathyroid hormone candidate in Phase I testing for osteoporosis; RT-105, an anti-TNF-alpha antibody in preclinical development for psoriatic arthritis; RT-110, a parathyroid hormone program for hypoparathyroidism; RT-116, a discovery-stage program targeting obesity; and RT-111, an ustekinumab biosimilar under development for inflammatory conditions. Rani Therapeutics also has a collaboration with ProGen Co., Ltd. on RT-114, which is being developed and commercialized for obesity. The company was founded in 2012 and is headquartered in San Jose, California.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.